Pediatric Kidney Transplant Without Calcineurin Inhibitors
Completed · Not applicable
Conditions studied: End-Stage Renal Disease
In brief
The purpose of this study is to see the effect of using drugs other than calcineurin inhibitors to improve the rate of kidney transplant failure. Kidney transplantation can help children with end-stage kidney disease. However, it has been difficult to find treatment for donor graft rejection that does not have a lot of side effects. Researchers hope to find treatments (immunosuppressants) with fewer side effects. One approach is to avoid using calcineurin inhibitors and to try a new drug known as sirolimus instead. Another is to use steroids less often. This study will test whether using sirolimus, fewer steroid treatments, MMF, and certain antibodies will improve long-term graft survival in children receiving kidney transplants from living donors.
Key facts
- Study ID
- NCT00023231
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 35
- Starts
- 2001-02-01
- Expected to finish
- 2006-08-01
- Last updated by the study team
- 2016-10-21
Who can join
Age: any, up to 21. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients may be eligible for this study if they:
- Are 21 years of age and under.
- Are kidney recipients of living-donor grafts, except when living-donor grafts are identically matched.
You may not qualify if…
- Patients will not be eligible for this study if they:
- Are recipients of identical (HLA matched) living-donor grafts.
- Are recipients of cadaver-donor grafts.
- Have certain abnormal kidney diseases that may return.
- Have failed 2 or more previous kidney transplants.
- Have fat abnormalities that are inherited or present at high levels.
Where it is running
- Lauren Schenker — Rockville, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.